- Regeneron Pharmaceuticals ( NASDAQ: REGN ) on Wednesday said the U.S. FDA had accepted its application requesting for an extended regimen for its Eylea injection to treat patients with diabetic retinopathy (DR).
- DR is when high blood sugar in diabetic patients damages the blood vessels in the retina.
- REGN's supplemental biologics license application is requesting a 16-week 2 mg dosing regimen for DR patients.
- Eylea is already approved to be used in a 4- and 8-week dosing regimen for DR patients.
- The FDA is set to decide on the supplemental application on or before Feb. 28, 2023.
- REGN stock +1.1% at $600.83 in morning trading.
For further details see:
FDA accepts Regeneron's application for Eylea extended regimen to treat diabetic blindness